Biotech Startups
9,585 companies tagged Biotech, with their investors and founders.
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
10 investors
Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.
10 investors
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.
10 investors
One.bio develops food products designed to provide beneficial molecular signals to support health and address chronic inflammatory disease. The company applies rigorous molecular science to food composition and production.
10 investors
Pivot Bio develops agricultural innovations focused on transforming farming practices through microbiology and genetics. The company serves farmers worldwide.
10 investors
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
10 investors
Proscia provides a digital pathology software platform that converts glass microscope slides into high-resolution digital images for viewing, management, and analysis by pathologists and research teams. The platform enables clinical laboratories and life sciences organizations to improve workflow efficiency, support remote collaboration, and integrate artificial intelligence tools for quantitative tissue analysis and biomarker detection.
10 investors
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
10 investors
Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials. The company develops treatments for ophthalmology and vision-related conditions.
10 investors
Strella makes sensors that monitor ethylene, the gas that drives ripening in fruits and vegetables, to track produce freshness across the supply chain. Its technology is used to help manage produce such as apples in the U.S. food supply.
10 investors
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies. The company aims to accelerate drug development and bring treatments to patients faster through precision-driven study design.
10 investors
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings. The company serves healthcare systems and clinicians with diagnostic instruments and solutions.
9 investors
Alga Biosciences develops feed additives that reduce methane emissions from cattle — cutting cow burps to combat climate change.
9 investors
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development. The company serves patients with cancer through novel drug candidates advancing in clinical trials.
9 investors
Apheris provides a platform enabling large global life sciences organizations to collaborate on sensitive, proprietary data and jointly train machine learning models on distributed datasets while maintaining privacy across teams, borders, and organizations.
9 investors
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization. The company focuses on oncology treatments guided by specific biologic mechanisms of cancer.
9 investors
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
9 investors
BenchSci provides a proprietary knowledge graph and curated biomedical dataset built from millions of research papers, patents, preprints, and databases, covering reagents such as antibodies, RNAi, CRISPR records, cell lines, and animal models. Its data platform (EMET) is aimed at supporting drug discovery and disease biology research.
9 investors
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
9 investors
Biobot pioneers wastewater epidemiology, monitoring pathogens and substances in sewage to provide real-time public health surveillance at the community level. The company serves public health agencies, vaccine manufacturers, and hospital systems globally.
9 investors
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
9 investors
Edison Scientific builds AI agents for scientific research, enabling researchers and industries to accelerate discovery across biology, chemistry, physics, and related domains. The company combines advances in large language models and scientific reasoning to automate experimental design, literature analysis, and scientific workflows.
9 investors
Epoch Biodesign develops enzyme recycling technology powered by AI to break down plastic and textile waste into virgin-grade chemical building blocks. The company serves the fashion, apparel, and automotive industries pursuing textile-to-textile and plastic circularity.
9 investors
Future Fields uses fruit flies as bioreactors to produce difficult-to-express proteins at scale for pharmaceutical, agricultural, and food applications. The company aims to enable the development of novel biological products across healthcare, agriculture, and nutrition sectors.
9 investors